Nicotinamide: an oral antimicrobial agent with activity against both Mycobacterium tuberculosis and human immunodeficiency virus.
about
The kynurenine pathway activities in a sub-Saharan HIV/AIDS populationC/EBPε mediates nicotinamide-enhanced clearance of Staphylococcus aureus in mice.Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.Treatment of tuberculosis in children.Targeting the host-pathogen interface for treatment of Staphylococcus aureus infection.Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.Exploring NAD+ metabolism in host-pathogen interactions.Efficient Synthesis of Nicotinamide-1-¹⁵N for Ultrafast NMR Hyperpolarization Using Parahydrogen.Nicotinamide inhibits the lysosomal cathepsin b-like protease and kills African trypanosomes.Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells.Kynurenine Pathway Pathologies: do Nicotinamide and Other Pathway Co-Factors have a Therapeutic Role in Reduction of Symptom Severity, Including Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM)Nicotinamide polymeric nanoemulsified systems: a quality-by-design case study for a sustained antimicrobial activity.Analysis of metabolomic profile of fermented Orostachys japonicus A. Berger by capillary electrophoresis time of flight mass spectrometryIn vitro antileishmanial activity of nicotinamide.Modulation of Mitochondrial Membrane Potential and ROS Generation by Nicotinamide in a Manner Independent of SIRT1 and MitophagyA Brief Historic Overview of Clinical Disorders Associated with Tryptophan: The Relevance to Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM).Possible role of cytokine-induced tryptophan degradation in anaemia of inflammation.Single-Scan Multidimensional NMR Analysis of Mixtures at Sub-Millimolar Concentrations by using SABRE Hyperpolarization.Acetylation of lysine 182 inhibits the ability of Mycobacterium tuberculosis DosR to bind DNA and regulate gene expression during hypoxia.
P2860
Q28386378-4D1C2696-C72F-4DDC-B3CD-AF53E89FA4A9Q34660816-A49024E5-0009-469A-B7AA-46C596126911Q34795203-7C8102F9-A5C2-4D04-9644-C5E37C7A30E7Q37340569-7B89ED68-6FA1-4B3B-9646-DF320DE5B7BCQ37957015-EBDC6AD3-724B-40F7-9C99-D6ADF996AF38Q38368943-0E2F67D7-C22B-4144-B60E-403B5FF79485Q38683395-26755343-FE6E-4870-9106-D5933E444883Q38892159-A2D5EE2B-8C5F-4ACB-89E9-4F48A7531008Q39188137-FF183590-83BA-4D17-81EE-2BB03728699EQ39247299-A9466E94-9312-48B3-A744-7470F7848568Q39371166-6804F663-4CA4-4981-B3FA-8B7E53A10B80Q40294190-6260B87E-6B56-41EC-8E6E-8BFBBAFD311BQ41008398-C7317407-DF02-4860-B84E-CFFE4C03B4A2Q41009075-64A1C654-CB99-430C-95F0-C01BF4060EFFQ41288627-988A610A-10AA-4282-9C49-9DAFAD59505DQ42562073-AE36F645-A14A-4B9B-8C47-29BE0509D4C2Q44763703-BA475D74-967A-4937-AA25-E8703363BEA4Q48142712-A1382228-094E-4CAA-8F6D-2DCB78311F1BQ55174955-E22C527F-C3BC-45AB-A1E4-9E3C08C14060
P2860
Nicotinamide: an oral antimicrobial agent with activity against both Mycobacterium tuberculosis and human immunodeficiency virus.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Nicotinamide: an oral antimicr ...... human immunodeficiency virus.
@ast
Nicotinamide: an oral antimicr ...... human immunodeficiency virus.
@en
type
label
Nicotinamide: an oral antimicr ...... human immunodeficiency virus.
@ast
Nicotinamide: an oral antimicr ...... human immunodeficiency virus.
@en
prefLabel
Nicotinamide: an oral antimicr ...... human immunodeficiency virus.
@ast
Nicotinamide: an oral antimicr ...... human immunodeficiency virus.
@en
P2860
P356
P1476
Nicotinamide: an oral antimicr ...... human immunodeficiency virus.
@en
P2093
Michael F Murray
P2860
P304
P356
10.1086/367544
P407
P577
2003-01-31T00:00:00Z